NCT04228406 - Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

December 31, 2020

Conditions

Solid TumorC-Met Mutation-Related Tumors

Interventions

DRUG

GST-HG161

There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .

Trial Locations (1)

200135

RECRUITING

Shanghai Oriental Hospital, Shanghai